News & Progress

Press Releases

September 17, 2020
Palleon Pharmaceuticals Raises $100 million Series B to Develop Drugs Targeting Glycan-Mediated Immune Regulation to Treat Cancer and Inflammatory Diseases
February 12, 2020
Palleon Pharmaceuticals Appoints Li Peng, Ph.D., as Chief Scientific Officer
November 19, 2019
Palleon Pharmaceuticals to Present Preclinical Data on EAGLE-Her2 and Anti-Siglec-9 Antibody Programs at the 11th Annual Protein & Antibody Engineering Summit
November 07, 2019
Palleon Pharmaceuticals to Present Preclinical Data on EAGLE and HYDRA Platforms at the Society for Immunotherapy of Cancer’s (SITC) 34th Annual Meeting

View All Press Releases

In the News

September 17, 2020
With details on lead sialoglycan degrader in place, Palleon raises $100M series B
BioCentury
Palleon battalion bags $100M series B for glycan push
BioWorld
Palleon Pharmaceuticals secures $100m in Series B funding
Pharmaceutical Technology
Jim Broderick reels in a $100M Series B to explore a ‘new and big’ angle of immune regulation
Endpoints

Publications & Posters

Poster
HYDRA Platform Development to Investigate Siglec-engaging Tumor Immunosuppressive Glyco-codes
Society for Immunotherapy of Cancer’s (SITC) 34th Annual Meeting, November 9, 2019, Abstract #P118
Poster
Blockade of Siglec/Sialoglycan Axis Using EAGLE Technology to Potentiate Anticancer Immunity
Society for Immunotherapy of Cancer’s (SITC) 34th Annual Meeting, November 8, 2019, Abstract #P273
Publication
Siglec-9 Regulates an Effector Memory CD8+ T-cell Subset That Congregates in the Melanoma Tumor Microenvironment
Cancer Immunology Research. April 23, 2019.
Poster
A Novel Therapeutic Modality of Inhibiting the Glyco-Immune Checkpoint Axis to Treat Cancer
American Association for Cancer Research, April 2019, Poster #LB-109

View All Publications & Posters

Social Media